Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Authors: Cunningham, A. P.; Love, W. K.; Zhang, R. W.; Andrews, L. G.; Tollefsbol, T. O.
Source: Current Medicinal Chemistry, Volume 13, Number 24, October 2006 , pp. 2875-2888(14)
Publisher: Bentham Science Publishers
Abstract:Current standard cancer therapies (chemotherapy and radiation) often cause serious adverse off-target effects. Drug design strategies are therefore being developed that will more precisely target cancer cells for destruction while leaving surrounding normal cells relatively unaffected. Telomerase, widely expressed in most human cancers but almost undetectable in normal somatic cells, provides an exciting drug target. This review focuses on recent pharmacogenomic approaches to telomerase inhibition. Antisense oligonucleotides, RNA interference, ribozymes, mutant expression, and the exploitation of differential telomerase expression as a strategy for targeted oncolysis are discussed here in the context of cancer therapeutics. Reports of synergism between telomerase inhibitors and traditional cancer therapeutic agents are also analyzed.
Document Type: Research Article
Affiliations: Department of Biology, 175 Campbell Hall, 1300 University Boulevard, University of Alabama at irmingham, Birmingham, AL 35294-1170, USA.
Publication date: October 1, 2006
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.